아토피 피부염 치료제 시장 규모, 점유율, 성장 분석 : 투여 경로별, 약물 종류별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Atopic Dermatitis Drugs Market size was valued at USD 16.28 Billion in 2024 and is poised to grow from USD 17.78 Billion in 2025 to USD 35.95 Billion by 2033, growing at a CAGR of 9.2% during the forecast period (2026-2033).

Market insights for Global Atopic Dermatitis Drugs market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Atopic Dermatitis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Atopic Dermatitis Drugs Market Segments Analysis

Global Atopic Dermatitis Drugs Market is segmented by Product Type, Drug Class, Therapy, Route of Administration, Distribution and region. Based on Product Type, the market is segmented into Biologics and Others. Based on Drug Class, the market is segmented into Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics and Others. Based on Therapy, the market is segmented into Photo Therapy and Directed Therapy. Based on Route of Administration, the market is segmented into Topical, Parenteral and Oral. Based on Distribution, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Other Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Atopic Dermatitis Drugs Market

The global market for atopic dermatitis drugs is experiencing growth driven by an increasing prevalence of the condition attributed to environmental changes, urbanization, and genetic factors. This rise in incidence is particularly notable among children and young adults, contributing to a heightened demand for effective therapeutic solutions. As awareness of atopic dermatitis expands and healthcare systems focus on improving treatment options, the need for innovative drugs tailored to manage this chronic skin condition is expected to strengthen, ultimately influencing market dynamics and encouraging further research and development in this field.

Restraints in the Global Atopic Dermatitis Drugs Market

The global market for atopic dermatitis drugs faces significant challenges due to the side effects associated with various treatments. Certain systemic immunosuppressants, while effective, can lead to serious complications such as infections or liver toxicity, raising concerns about long-term patient safety. These adverse effects can negatively impact patients' quality of life, ultimately hindering the growth potential of the atopic dermatitis drugs market. As more patients and healthcare providers weigh the benefits against the risks of these medications, the overall acceptance and utilization of atopic dermatitis drugs may be adversely affected, creating a restraint in market expansion.

Market Trends of the Global Atopic Dermatitis Drugs Market

The Global Atopic Dermatitis Drugs market is increasingly leaning toward the adoption of JAK (Janus kinase) inhibitors due to their ability to provide rapid symptom relief and effectively address the unmet needs of patients. These innovative treatments, exemplified by drugs like upadacitinib and abrocitinib, are gaining prominence for their efficacy in managing atopic dermatitis symptoms, thereby enhancing patient quality of life. As the market evolves, a strategic focus on JAK inhibitors is expected to significantly shape the competitive landscape, offering drug providers new opportunities for growth and expansion while meeting the rising demand for effective therapeutic solutions in dermatology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Atopic Dermatitis Drugs Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Biologics
• Others

Global Atopic Dermatitis Drugs Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Corticosteroids
• Calcineurin Inhibitors
• PDE4 Inhibitors
• Biologics
• Others

Global Atopic Dermatitis Drugs Market Size by Therapy & CAGR (2026-2033)

• Market Overview
• Photo Therapy
• Directed Therapy

Global Atopic Dermatitis Drugs Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Topical
• Parenteral
• Oral

Global Atopic Dermatitis Drugs Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Other Pharmacies

Global Atopic Dermatitis Drugs Market Size & CAGR (2026-2033)

• North America (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • US
  • Canada
• Europe (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galderma S.A. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leo Pharma A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almirall, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations